Literature DB >> 28109680

Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions.

T Balasopoulos1, A Charonis2, K Athanasakis1, J Kyriopoulos1, E Pavi1.   

Abstract

OBJECTIVES: Since 2010, the memoranda of understanding were implemented in Greece as a measure of fiscal adjustment. Public pharmaceutical expenditure was one of the main focuses of this implementation. Numerous policies, targeted on pharma spending, reduced the pharmaceutical budget by 60.5%. Yet, generics' penetration in Greece remained among the lowest among OECD countries. This study aims to highlight the factors that affect the perceptions of the population on generic drugs and to suggest effective policy measures.
METHODOLOGY: The empirical analysis is based on a national cross-sectional survey that was conducted through a sample of 2003 individuals, representative of the general population. Two ordinal logistic regression models were constructed in order to identify the determinants that affect the respondents' beliefs on the safety and the effectiveness of generic drugs.
FINDINGS: The empirical findings presented a positive and statistically significant correlation with income, bill payment difficulties, safety and effectiveness of drugs, prescription and dispensing preferences and the views toward pharmaceutical companies. Also, age and trust toward medical community have a positive and statistically significant correlation with the perception on the safety of generic drugs. Policy interventions are suggested on the bases of the empirical results on 3 major categories; (a) information campaigns, (b) incentives to doctors and pharmacists and (c) to strengthen the bioequivalence control framework and the dissemination of results.
Copyright © 2017 Elsevier B.V. All rights reserved.

Keywords:  Drugs; Generic; Health policy; Pharmaceutical policy

Mesh:

Substances:

Year:  2017        PMID: 28109680     DOI: 10.1016/j.healthpol.2016.12.011

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  3 in total

1.  The incidence of recurrent cardiovascular events among acute coronary syndrome patients treated with generic or original clopidogrel in relation to their sociodemographic and clinical characteristics. The Aegean study.

Authors:  Nikolaos G Patsourakos; Matina Kouvari; Apostolos Kotidis; Kallirroi I Kalantzi; Maria E Tsoumani; Filippos Anastasiadis; Panagiotis Andronikos; Theano Aslanidou; Petros Efraimidis; Anastasios Georgiopoulos; Kalliopi Gerakiou; Eleni Grigoriadou-Skouta; Panagiotis Grigoropoulos; Dionysios Hatzopoulos; Athanasios Kartalis; Anastasios Lyras; Gerasimos Markatos; Aristeidis Mikrogeorgiou; Ioannis Myroforou; Anestis Orkopoulos; Pavlos Pavlidis; Charalampos Petras; Maria Riga; Marina Skouloudi; Nikolaos Smyrnioudis; Konstantinos Thomaidis; Grammatiki E Tsikouri; Emmanuel I Tsikouris; Konstantinos Zisimos; Panagiotis Vavoulis; Maria-Gabriella Vitali; George Vitsas; Constantinos Vogiatzidis; Stylianos Chantanis; Stefanos Fousas; Demosthenes B Panagiotakos; Alexandros D Tselepis
Journal:  Arch Med Sci       Date:  2020-05-30       Impact factor: 3.318

2.  A nationwide survey exploring physicians' and pharmacists' knowledge, awareness and perceptions regarding generic medicines in China.

Authors:  Jinghan Qu; Wei Zuo; Roxane L Took; Kenneth W Schafermeyer; Stephanie Lukas; Shaohong Wang; Liping Du; Xin Liu; Yang Gao; Jiantao Li; Hui Pan; Xiaoli Du; Dan Mei; Bo Zhang
Journal:  BMC Health Serv Res       Date:  2022-08-20       Impact factor: 2.908

3.  What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.

Authors:  Kate MacKrill; Keith J Petrie
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.